Stock Ratings / Health Care / LONA / forecast

TIL (51) IMA (24) CRBU (43) INMB (45) ⌘ Pro Terminal →

LeonaBio Inc. (LONA) 12-Month Stock Forecast & Price Target Cone

$4.91 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.89

LeonaBio Inc. (LONA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $46.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.89 (-0.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LONA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY LONA SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 43.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$5.75-9.6% Next Q

Q2 (-2Q)

Grade D$5.20-6.9% Next Q

Q3 (-1Q)

Grade D$4.84+1.4% Next Q

Current

Grade D-$4.91-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LONA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LONA currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.05) and Max Pain ($5.16) forces dealer call-delta covering toward $14.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LONA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LONA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LONA Position Size: $10,000

Shares at $4.91: 2036.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.56

$7,251

$-2,749 (-27.5%)

12M Consensus BaseTarget $4.56

$9,287

$-713 (-7.1%)

12M Bull Case BreakoutTarget $14.92

$30,387

+$20,387 (+203.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$5	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$14	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LONA)

✓Walkthrough of LONA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LONA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.04%▼ DESCENDING CHANNEL

2026-10-30O $4.89H $5.14L $4.76C $4.91VOL 43.1K

RES: $6.50SUP: $0.37SMA50: $6.05SMA200: $7.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LONA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LONA Butterfly Map → + Track LONA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LONA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LONA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LONA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LONA)

Health Care Rank #587 of 1016 ⚔️ TIL vs LONA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LONA vs. TIL, IMA, CRBU, INMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LeonaBio Inc. (LONA) ranks #587 by composite RQD confidence (42/100, grade D-) and #761 by equity capitalization ($46.3M). Within this direct 5-issuer industry benchmark cohort, LONA leads on earnings valuation at N/A trailing P/E, while LONA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with LONA at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LONA ACTIVE LeonaBio Inc.	D-	42/100	—	—	-35.0%	-1.01%	$46.3M	Benchmark Subject
TIL Instil Bio Inc.	D	51/100	—	—	-35.0%	+0.52%	$46.3M	/til-vs-lona →
IMA ImageneBio Inc.	E	24/100	—	—	-35.0%	-3.57%	$46.0M	/ima-vs-lona →
CRBU Caribou Biosciences Inc.	D-	43/100	—	—	-35.0%	-9.07%	$47.7M	/crbu-vs-lona →
INMB INmune Bio Inc.	D	45/100	—	—	-35.0%	+4.58%	$44.4M	/inmb-vs-lona →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001620463

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeonaBio Inc. (LONA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$106.0M, operating cash flow of -$45.7M, and free cash flow of -$45.7M (+53.0% YoY). On the balance sheet, LONA closed FY2025 with $92.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$106.0M	-$45.7M	-$45.7M	$92.2M	—
FY2024 (FY)	2024-12-31	$0	-$97.0M	-$97.2M	-$97.2M	$58.8M	—
FY2023 (FY)	2023-12-31	$0	-$117.7M	-$100.8M	-$100.8M	—	—

3. LONA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LONA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LeonaBio Inc. (NASDAQ: LONA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $4.91 (-1.01% 1D, market cap $46.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LONA ranks #587 in composite RQD confidence.

How does LONA compare to TIL and IMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LONA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and IMA (ImageneBio Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M). Among the 5-stock peer group, LONA leads on earnings multiple (N/A) while LONA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LONA?

Per LONA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001620463), LeonaBio Inc. generated $0 in revenue, -$106.0M in net income, and -$45.7M in free cash flow against $92.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LONA trading relative to its 50-day, 200-day, and 52-week technical levels?

LONA last traded at $4.91 (-1.01% on volume of 162,059 shares), positioning the stock -18.84% below its 50-day simple moving average ($6.05) and -34.62% below its 200-day simple moving average ($7.51). Across its 52-week range of $2.21 to $14.21, LONA sits at the 22.5% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.30 to $5.52).

LONA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LONA's 12-month stock price target?

LeonaBio Inc. (LONA) carries a 12-month consensus base price target of $4.56 (-7.1% from $4.91), with a bull-case target of $14.92 and a bear-case floor of $3.56.

Is LONA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates LONA D- (Sell — SELL) with an RQD Confidence score of 42/100.

Direct Sub-Reports: LONA RQD Cockpit LONA 12M Forecast LONA Earnings & Move LONA Dividends & DRIP LONA Insiders & 13F LONA Whale Options LONA Profit Sankey LONA News & Why